Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial-Reference-Cited by-同舟云学术

Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Published:2014-12 Issue:13 Volume:15 Page:1493-1502
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Coudert Bruno,Pierga Jean-Yves,Mouret-Reynier Marie-Ange,Kerrou Kaldoun,Ferrero Jean-Marc,Petit Thierry,Kerbrat Pierre,Dupré Pierre-François,Bachelot Thomas,Gabelle Philippe,Giard Sylvia,Coeffic David,Bougnoux Philippe,Prevost Jean-Briac,Paintaud Gilles,Thibault Gilles,Hernandez Juana,Coudert Mathieu,Arnould Laurent,Berriolo-Riedinger Alina

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer;Buzdar;J Clin Oncol,2005

2. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

3. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate;Amat;Br J Cancer,2003

4. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial;Coudert;Ann Oncol,2006

5. Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy;Guiu;Ann Oncol,2011

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of [18F]FDG PET/CT in patients with no special type breast cancer: Literature review and comparison between guidelines;The Breast;2024-09

2. Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer;Current Treatment Options in Oncology;2024-08-17

3. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-05-14

4. Quantitative ultrasound radiomics guided adaptive neoadjuvant chemotherapy in breast cancer: early results from a randomized feasibility study;Frontiers in Oncology;2024-04-19

5. Usefulness of interim contrast-enhanced breast MRI for predicting response of breast cancer to neoadjuvant chemotherapy;2024-04-12